Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy Participants
Interventions: Casdatifan, Itraconazole, Phenytoin; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pain
Interventions: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Adults
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Lung Cancer
Interventions: DNA/RNA sequencing and expression levels, Protein expression analysis, Lung tumor biopsy, Blood sample; Genetic · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: Up to 120 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK2269557 ELLIPTA DPI, Placebo ELLIPTA DPI, Activated charcoal; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Malignant Neoplasm of Breast, Breast Cancer
Interventions: Genomically Directed Monotherapy, Observation/Standard Therapy; Drug · Other
Lead sponsor: Bryan Schneider, MD; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 29
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 24 more

Conditions: Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH), Non-Langerhans-Cell Histiocytosis
Interventions: Genetic testing; Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy Volunteers
Interventions: AG-181, Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Convergence Insufficiency
Interventions: office-based vergence/accommodative therapy; Procedure
Lead sponsor: Salus University; Other
Eligibility: 9 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dental Caries
Interventions: Inactive supplement, Tricalcium phosphate supplement, Calcium carbonate supplement, Calcium citrate supplement, Inactive supplement and fluoride mouthwash, Calcium carbonate supplement and fluoride mouthwash, Calcium citrate supplement and fluoride mouthwash; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy Volunteer
Interventions: Pirfenidone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Merritt Island, Florida

Conditions: Appendiceal Cancer, Appendiceal Adenocarcinoma
Interventions: DNA Methylation Profiling, m6A Epitranscriptomic Profiling; Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durate, California

Conditions: Healthy
Interventions: Treatment A digoxin, Treatment B LX4211, Treatment C Digoxin + 400 mg LX4211 administered concomitantly; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Suspicion of, or Known Breast Cancer
Interventions: Radiology/MRI scan; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 5
States / cities: Duarte, California • San Francisco, California • Iowa City, Iowa + 2 more

Conditions: Lower Extremity Muscular Power Performance Output
Interventions: Body tempering, Foam rolling self-myofascial release; Other
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years to 39 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Cognition Disorders in Old Age, Mild Cognitive Impairment, Cognitive Decline
Interventions: Niagen, Placebo Comparator; Dietary Supplement
Lead sponsor: Steven E Arnold, MD; Other
Eligibility: 60 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Metastatic Breast Cancer
Interventions: Normal Eating, Prolonged Fasting; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Subjects
Interventions: (Treatment A), (Treatment B); Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Diabetes Mellitus, Type 1
Interventions: OPT101; Drug
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Walnut Creek, California • Renton, Washington

Conditions: Prostate Cancer, Vitamin D Deficiency, Stress Reaction
Interventions: cholecalciferol, Standard of Care Prostate Biopsy - collection of 13th core for RNA-seq, Standard of Care Prostate Biopsies at baseline and after one year vitamin D3 supplementation, Allostatic Load; Drug · Procedure · Diagnostic Test
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Major Depressive Disorder
Interventions: Tai Chi; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Airway Control, Anesthesia, Intubation, Complication
Interventions: Ketamine, Etomidate; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteers
Interventions: DC-806, Itraconazole, Carbamazepine; Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease

Single and Multiple Ascending Dose Study and Food Effect Study for AG181

Objective Assessment of Disparity Vergence After Treatment of Symptomatic CI in Children

Effect of Chewing a Calcium Supplement Before Fluoride Rinse on Salivary Fluoride

A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants

Molecular Profiling for Risk Stratification in Appendiceal Cancer

DDI Study With Multiple-dose LX4211 and Single Dose Digoxin

Breast MRI Spectroscopy

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

The Immediate and 24-hour Effects of Body Tempering Versus Foam Rolling on Lower Extremity Muscular Power During the Vertical Jump and Standing Long Jump Tests

Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment

Fast-Her: Fasting Effects on Breast Cancer Treatment

Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

OPT101 in Type 1 Diabetes Patients

Vitamin D Supplementation in RNA-seq Profiles of Single-core Prostate Samples, Among Veterans

Tai Chi Training for Treating Depressed Chinese Americans

Ketamine Versus Etomidate for Rapid Sequence Intubation

A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants